Prostate Cancer Resource Books

Posted by Pharmaceutical-Stuff on Monday 10 March 2008

:

Here is a list of books that contain informations on , i know its such a big list but i had to cover any aspects of the , so this list will include absolute everything, you can start reading.

  1. Albertsen PC, Fryback DG, Storer BE, et al: The impact of co-morbidity on life expectancy among men with localized . J Urol 1996 Jul; 156(1): 127-32[Medline].
  2. Albertsen PC, Fryback DG, Storer BE, et al: Long-term survival among men with conservatively treated localized . JAMA 1995 Aug 23-30; 274(8): 626-31[Medline].
  3. Amling CL, Kane CJ, Riffenburgh RH, et al: Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 2001 Nov; 58(5): 723-8[Medline].
  4. Berthon P, Valeri A, Cohen-Akenine A, et al: Predisposing gene for -onset , localized on chromosome 1q42.2-43. Am J Hum Genet 1998 Jun; 62(6): 1416-24[Medline].
  5. Bostwick DG: Prostatic intraepithelial neoplasia (PIN): current concepts. J Cell Biochem Suppl 1992; 16H: 10-9[Medline].
  6. Bostwick DG, Qian J: High-grade prostatic intraepithelial neoplasia. Mod Pathol 2004 Mar; 17(3): 360-79[Medline].
  7. Bratt O, Kristoffersson U, Lundgren R, Olsson H: Familial and hereditary in southern Sweden. A population-based case-control study. Eur J 1999 Feb; 35(2): 272-7[Medline].
  8. Carter BS, Bova GS, Beaty TH, et al: Hereditary : epidemiologic and clinical features. J Urol 1993 Sep; 150(3): 797-802[Medline].
  9. Carter HB, Epstein JI, Chan DW, et al: Recommended -specific antigen testing intervals for the detection of curable . JAMA 1997 May 14; 277(18): 1456-60[Medline].
  10. Catalona WJ, Smith DS, Ornstein DK: detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign examination. Enhancement of specificity with free PSA measurements. JAMA 1997 May 14; 277(18): 1452-5[Medline].
  11. Chodak GW, Thisted RA, Gerber GS, et al: of conservative management of clinically localized . N Engl J Med 1994 Jan 27; 330(4): 242-8[Medline].
  12. Djavan B, Susani M, Bursa B, et al: Predictability and significance of multifocal in the radical prostatectomy specimen. Tech Urol 1999 Sep; 5(3): 139-42[Medline].
  13. Etzioni R, Legler JM, Feuer EJ, et al: surveillance series: interpreting trends in –part III: Quantifying the link between population -specific antigen testing and recent declines in mortality. J Natl Inst 1999 Jun 16; 91(12): 1033-9[Medline].
  14. Feuer EJ, Merrill RM, Hankey BF: surveillance series: interpreting trends in –part II: Cause of death misclassification and the recent rise and fall in mortality. J Natl Inst 1999 Jun 16; 91(12): 1025-32[Medline].
  15. Gleason DF: Histologic grading of : a perspective. Hum Pathol 1992 Mar; 23(3): 273-9[Medline].
  16. Graversen PH, Nielsen KT, Gasser TC, et al: Radical prostatectomy versus expectant primary treatment in stages I and II prostatic . A fifteen-year follow-up. Urology 1990 Dec; 36(6): 493-8[Medline].
  17. Greene FL, Sobin LH: The TNM system: our language for care. J Surg Oncol 2002 Jul; 80(3): 119-20[Medline].
  18. Hoffman RM, Gilliland FD, Eley JW, et al: Racial and ethnic differences in advanced-stage : the Outcomes Study. J Natl Inst 2001 Mar 7; 93(5): 388-95[Medline].
  19. Holmberg L, Bill-Axelson A, Helgesen F, et al: A randomized trial comparing radical prostatectomy with watchful waiting in . N Engl J Med 2002 Sep 12; 347(11): 781-9[Medline].
  20. Hsing AW, Tsao L, Devesa SS: International trends and patterns of incidence and mortality. Int J 2000 Jan 1; 85(1): 60-7[Medline].
  21. Hsing AW, Comstock GW: Serological precursors of : serum hormones and risk of subsequent . Epidemiol Biomarkers Prev 1993 Jan-Feb; 2(1): 27-32[Medline].
  22. Iczkowski KA, Chen HM, Yang XJ, Beach RA: diagnosed after initial biopsy with atypical small acinar proliferation suspicious for malignancy is similar to found on initial biopsy. Urology 2002 Nov; 60(5): 851-4[Medline].
  23. Iczkowski KA, Bassler TJ, Schwob VS, et al: Diagnosis of “suspicious for malignancy” in biopsies: predictive value for . Urology 1998 May; 51(5): 749-57; discussion 757-8[Medline].
  24. Jemal A, Murray T, Samuels A, et al: statistics, 2003. CA J Clin 2003 Jan-Feb; 53(1): 5-26[Medline].
  25. Johansson JE, Andrén O, Andersson SO, et al: Natural history of , localized . JAMA 2004 Jun 9; 291(22): 2713-9[Medline].
  26. Klein EA, Thompson IM, Lippman SM, et al: SELECT: the Selenium and Vitamin E Prevention Trial: rationale and design. Prostatic Dis 2000 Nov; 3(3): 145-151[Medline].
  27. Kolonel LN, Nomura AM, Cooney RV: Dietary fat and : current status. J Natl Inst 1999 Mar 3; 91(5): 414-28[Medline].
  28. Labrie F, Candas B, Dupont A, et al: Screening decreases death: first analysis of the 1988 Quebec prospective randomized controlled trial. 1999 Feb 1; 38(2): 83-91[Medline].
  29. Langer JE, Rovner ES, Coleman BG, et al: Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by needle biopsy. J Urol 1996 Jan; 155(1): 228-31[Medline].
  30. Lee F, Siders DB, Torp-Pedersen ST, et al: : transrectal ultrasound and pathology comparison. A preliminary study of outer gland (peripheral and central zones) and inner gland (transition zone) . 1991 Feb 15; 67(4 Suppl): 1132-42[Medline].
  31. McCahy PJ, Harris CA, Neal DE: Breast and in the relatives of men with . Br J Urol 1996 Oct; 78(4): 552-6[Medline].
  32. Morgan TO, Jacobsen SJ, McCarthy WF, et al: Age-specific reference ranges for -specific antigen in black men. N Engl J Med 1996 Aug 1; 335(5): 304-10[Medline].
  33. Moyad MA: Soy, disease prevention, and . Semin Urol Oncol 1999 May; 17(2): 97-102[Medline].
  34. Ndubuisi SC, Kofie VY, Andoh JY, Schwartz FM: Black-white differences in the stage at presentation of in the District of Columbia. Urology 1995 Jul; 46(1): 71-7[Medline].
  35. Punglia RS, D’Amico AV, Catalona WJ, et al: Effect of verification bias on screening for by measurement of -specific antigen. N Engl J Med 2003 Jul 24; 349(4): 335-42[Medline].
  36. Rodríguez C, Calle EE, Tatham LM, et al: Family history of breast as a predictor for fatal . Epidemiology 1998 Sep; 9(5): 525-9[Medline].
  37. Ruijter ET, Miller GJ, van de Kaa CA, et al: Molecular analysis of multifocal lesions. J Pathol 1999 Jul; 188(3): 271-7[Medline].
  38. Sellers TA, Potter JD, Rich SS, et al: Familial clustering of breast and cancers and risk of postmenopausal breast . J Natl Inst 1994 Dec 21; 86(24): 1860-5[Medline].
  39. Smith JR, Freije D, Carpten JD, et al: Major susceptibility locus for on chromosome 1 suggested by a genome-wide search. Science 1996 Nov 22; 274(5291): 1371-4[Medline].
  40. Stemmermann GN, Nomura AM, Chyou PH, Yatani R: A prospective comparison of at autopsy and as a clinical event: the Hawaii Japanese experience. Epidemiol Biomarkers Prev 1992 Mar-Apr; 1(3): 189-93[Medline].
  41. Theodorescu D, Broder SR, Boyd JC, et al: p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the . J Urol 1997 Jul; 158(1): 131-7[Medline].
  42. Theodorescu D, Frierson HF, Sikes RA: Molecular determination of surgical margins using fossa biopsies at radical prostatectomy. J Urol 1999 May; 161(5): 1442-8[Medline].
  43. Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of . N Engl J Med 2003 Jul 17; 349(3): 215-24[Medline].
  44. Walsh PC, Vaughan ED, Retik AB, Wein A, eds: Campbell’s Urology. Vol 3. 7th ed. Philadelphia, Pa: WB Saunders; 1998: 2487-656.
  45. Weinrich MC, Jacobsen SJ, Weinrich SP, et al: Reference ranges for serum -specific antigen in black and white men without . Urology 1998 Dec; 52(6): 967-73[Medline].
  46. Whitmore WF Jr: Expectant management of clinically localized prostatic . Semin Oncol 1994 Oct; 21(5): 560-8[Medline].
  47. Xu J, Meyers D, Freije D, et al: Evidence for a susceptibility locus on the X chromosome. Nat Genet 1998 Oct; 20(2): 175-9[Medline].
  48. Yatani R, Shiraishi T, Nakakuki K, et al: Trends in frequency of latent carcinoma in Japan from 1965-1979 to 1982-1986. J Natl Inst 1988 Jul 6; 80(9): 683-7[Medline].
  49. Zimmerman SM: Factors influencing Hispanic participation in screening. Oncol Nurs Forum 1997 Apr; 24(3): 499-504[Medline].

Tags: , ,

Related posts

Posted in Uncategorized

Leave a Reply